NCT05293704View on ClinicalTrials.gov

An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients

PHASE4UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

May 1, 2024

Conditions

Kidney Transplant RecipientsBK Virus

Interventions

DRUG

Mizoribine

Orally administered at 3-4 mg/kg/d, once every 12 hours; When body weight ≤50 kg, each dose of 75 mg; Weight \& gt At 50 kg, the dosage was 100 mg each time.

Trial Locations (1)

Unknown

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou